Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Hyper-CVAD Plus Imatinib Mesylate (Gleevec, STI571) for Philadelphia-Positive Acute Lymphocytic Leukemia

X
Trial Profile

Phase II Study of Hyper-CVAD Plus Imatinib Mesylate (Gleevec, STI571) for Philadelphia-Positive Acute Lymphocytic Leukemia

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Granulocyte colony-stimulating factors; Mesna; Methotrexate; Methotrexate; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 May 2023 Results evaluating its efficacy ponatinib versus imatinib-based regimens using a matching adjusted indirect comparison from NCT00038610 , NCT00327678, NCT01424982 and NCT01641107; published in the Advances in Therapy
    • 09 Nov 2022 Results of a matched adjusting Indirect comparison in two studies (GRAAPH-2005 and NCT00038610) assessing efficacy of ponatinib as frontline treatment in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia were presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 01 Apr 2021 Results assessing the prognostic factors for progression and survival and to the role of ASCT in patients who achieve a CMR within 3 months of therapy using data from NCT00038610, NCT00390793, and NCT01424982 published in the Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top